Last reviewed · How we verify
SYR-322-MET
SYR-322-MET is a GLP-1 receptor agonist Small molecule drug developed by Takeda. It is currently in Phase 3 development for Type 2 diabetes.
SYR-322-MET is a glucagon-like peptide-1 (GLP-1) receptor agonist.
SYR-322-MET is a glucagon-like peptide-1 (GLP-1) receptor agonist. Used for Type 2 diabetes.
At a glance
| Generic name | SYR-322-MET |
|---|---|
| Sponsor | Takeda |
| Drug class | GLP-1 receptor agonist |
| Target | GLP-1R |
| Modality | Small molecule |
| Therapeutic area | Diabetes |
| Phase | Phase 3 |
Mechanism of action
It works by mimicking the action of the natural hormone GLP-1 to help lower blood sugar levels. This is achieved by enhancing glucose-dependent insulin secretion, suppressing inappropriately elevated glucagon secretion, and slowing gastric emptying.
Approved indications
- Type 2 diabetes
Common side effects
- Nausea
- Vomiting
- Diarrhea
Key clinical trials
- The Effect of Alogliptin Combined With Actoplus Met on Glucose and Lipid Metabolism and Pancreatic Function in Patients With T2DM Complicated With MAFLD (PHASE4)
- Effect of Food on the Pharmacokinetics of Single Oral Dose Administration of a Fixed-Dose Combination of SYR-322 and Metformin Hydrochloride in Healthy Adult Male Subjects (PHASE3)
- A Bioequivalence Study of CT-L01 Compared to Co-administration (ALO 12.5 mg and MET XR 500 mg) in Healthy Volunteers (PHASE1)
- A Bioequivalence Study of CT-L01 Compared to Co-administration (ALO 25 mg and MET XR 1,000 mg) in Healthy Volunteers (PHASE1)
- Effect of Alogliptin/Pioglitazone on the Preservation of Long-term Beta-cell Function (PHASE4)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- SYR-322-MET CI brief — competitive landscape report
- SYR-322-MET updates RSS · CI watch RSS
- Takeda portfolio CI
Frequently asked questions about SYR-322-MET
What is SYR-322-MET?
How does SYR-322-MET work?
What is SYR-322-MET used for?
Who makes SYR-322-MET?
What drug class is SYR-322-MET in?
What development phase is SYR-322-MET in?
What are the side effects of SYR-322-MET?
What does SYR-322-MET target?
Related
- Drug class: All GLP-1 receptor agonist drugs
- Target: All drugs targeting GLP-1R
- Manufacturer: Takeda — full pipeline
- Therapeutic area: All drugs in Diabetes
- Indication: Drugs for Type 2 diabetes